title: Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients undergoing either hemodialysis or continuous ambulatory peritoneal dialysis.
abstract: OBJECTIVE
  To investigate the abnormalities of cellular immune responses in patients on hemodialysis (HD) and in those on continuous ambulatory peritoneal dialysis (CAPD).
  
  
  METHODS
  Forty-five (45) healthy volunteers, 34 patients on HD therapy, and 37 patients on CAPD were recruited for the present study. Lymphocyte subpopulations (CD2+, CD3+, CD3+/CD4+, CD3+/CD8+, CD3-/16+56+, CD19, and CD4/CD8) were determined by flow cytometry.
  
  
  RESULTS
  Lymphopenia, decreased absolute counts, and altered percentage values of CD3+, CD3+/ 4+, and CD19+ subpopulations were found in both patient groups. The HD and CAPD patients showed increased percentages of natural killer cells (CD3-/16+56+) compared to controls but CD4+/CD8+ ratio showed no significant changes among uremic patients and controls.
  
  
  CONCLUSIONS
  Replacement therapy may contribute to the quantitative alterations of immune subsets found in HD and CAPD patients compared to normal subjects. We speculate that these changes account, at least in part, for the immune dysregulation observed in patients with chronic renal failure. Analysis of lymphocyte subsets will help the research and the evaluation of the possible causes of immunodeficiency in uremic patients undergoing replacement therapy and will probably contribute to more efficient and preventive strategies.
authors.affiliation: Nephrology Department, Papageorgiou General Hospital, Thessaloniki, Greece. giannisgriv@hotmail.com
authors.forename: Ioannis
authors.initials: I
authors.lastname: Griveas
authors.forename: George
authors.initials: G
authors.lastname: Visvardis
authors.forename: Aleka
authors.initials: A
authors.lastname: Fleva
authors.forename: Dorothea
authors.initials: D
authors.lastname: Papadopoulou
authors.forename: Eftathios
authors.initials: E
authors.lastname: Mitsopoulos
authors.forename: Parthena
authors.initials: P
authors.lastname: Kyriklidou
authors.forename: Eleni
authors.initials: E
authors.lastname: Manou
authors.forename: Evdoxia
authors.initials: E
authors.lastname: Ginikopoulou
authors.forename: Daphni
authors.initials: D
authors.lastname: Meimaridou
authors.forename: Aikaterini
authors.initials: A
authors.lastname: Paulitou
authors.forename: George
authors.initials: G
authors.lastname: Sakellariou
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D017583:Hemodiafiltration; D006801:Humans; D007111:Immunity, Cellular; D016130:Immunophenotyping; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D016896:Treatment Outcome; D014511:Uremia / Q000276:immunology* / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal